215 related articles for article (PubMed ID: 28302763)
1. Phase 2 Study of
Goffin KE; Joniau S; Tenke P; Slawin K; Klein EA; Stambler N; Strack T; Babich J; Armor T; Wong V
J Nucl Med; 2017 Sep; 58(9):1408-1413. PubMed ID: 28302763
[No Abstract] [Full Text] [Related]
2. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection.
Briganti A; Abdollah F; Nini A; Suardi N; Gallina A; Capitanio U; Bianchi M; Tutolo M; Passoni NM; Salonia A; Colombo R; Freschi M; Rigatti P; Montorsi F
Eur Urol; 2012 Jun; 61(6):1132-8. PubMed ID: 22099610
[TBL] [Abstract][Full Text] [Related]
3.
Yılmaz B; Şahin S; Ergül N; Çolakoğlu Y; Baytekin HF; Sökmen D; Tuğcu V; Taşçı Aİ; Çermik TF
Ann Nucl Med; 2022 Jul; 36(7):597-609. PubMed ID: 35426599
[TBL] [Abstract][Full Text] [Related]
4. [
Li B; Ding X; Duan L; Shi J; Tang M; Zhang J; Zhao Z; Wu X; Gao Y
Front Endocrinol (Lausanne); 2024; 15():1326858. PubMed ID: 38449842
[TBL] [Abstract][Full Text] [Related]
5. The Value of
Su HC; Zhu Y; Hu SL; Liu C; Lin GW; Dai B; Zhang YJ; Ye DW
Ann Surg Oncol; 2019 Feb; 26(2):653-659. PubMed ID: 30324468
[TBL] [Abstract][Full Text] [Related]
6. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.
Gandaglia G; Fossati N; Zaffuto E; Bandini M; Dell'Oglio P; Bravi CA; Fallara G; Pellegrino F; Nocera L; Karakiewicz PI; Tian Z; Freschi M; Montironi R; Montorsi F; Briganti A
Eur Urol; 2017 Oct; 72(4):632-640. PubMed ID: 28412062
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study.
Gandaglia G; Mazzone E; Stabile A; Pellegrino A; Cucchiara V; Barletta F; Scuderi S; Robesti D; Leni R; Samanes Gajate AM; Picchio M; Gianolli L; Brembilla G; De Cobelli F; van Oosterom MN; van Leeuwen FWB; Montorsi F; Briganti A
Eur Urol; 2022 Oct; 82(4):411-418. PubMed ID: 35879127
[TBL] [Abstract][Full Text] [Related]
8. External validation of the updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection.
Gacci M; Schiavina R; Lanciotti M; Masieri L; Serni S; Vagnoni V; Abdollah F; Carini M; Martorana G; Montorsi F
Urol Int; 2013; 90(3):277-82. PubMed ID: 23296120
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD
BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
[TBL] [Abstract][Full Text] [Related]
10. PSMA SPECT/CT with
Schmidkonz C; Goetz TI; Kuwert T; Ritt P; Prante O; Bäuerle T; Goebell P; Cordes M
Ann Nucl Med; 2019 Dec; 33(12):891-898. PubMed ID: 31502084
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Accuracy of
Cantiello F; Gangemi V; Cascini GL; Calabria F; Moschini M; Ferro M; Musi G; Butticè S; Salonia A; Briganti A; Damiano R
Urology; 2017 Aug; 106():139-145. PubMed ID: 28438628
[TBL] [Abstract][Full Text] [Related]
12. Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study.
Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Mollenhauer M; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R
Eur Urol; 2014 Aug; 66(2):222-9. PubMed ID: 23465520
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Lymph Node Invasion in Patients with Clinically Localized Prostate Cancer Who Undergo Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: The Role of Obesity.
Tafuri A; Rizzetto R; Amigoni N; Sebben M; Shakir A; Gozzo A; Odorizzi K; Gallina S; Bianchi A; Ornaghi P; Brunelli M; Migliorini F; Cerruto MA; Artibani W; Siracusano S; Antonelli A; Porcaro AB
Urol Int; 2021; 105(5-6):362-369. PubMed ID: 33059351
[TBL] [Abstract][Full Text] [Related]
14. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
Liu C; Zhu Y; Su H; Xu X; Zhang Y; Ye D; Hu S
Prostate; 2018 Dec; 78(16):1215-1221. PubMed ID: 30027591
[TBL] [Abstract][Full Text] [Related]
15. Reliability of sentinel node procedure for lymph node staging in prostate cancer patients at high risk for lymph node involvement.
Van den Bergh L; Joniau S; Haustermans K; Deroose CM; Isebaert S; Oyen R; Mottaghy FM; Ameye F; Berkers J; Van Poppel H; Lerut E
Acta Oncol; 2015 Jun; 54(6):896-902. PubMed ID: 25591936
[TBL] [Abstract][Full Text] [Related]
16. Detection rate and operating time required for gamma probe-guided sentinel lymph node resection after injection of technetium-99m nanocolloid into the prostate with and without preoperative imaging.
Warncke SH; Mattei A; Fuechsel FG; Z'Brun S; Krause T; Studer UE
Eur Urol; 2007 Jul; 52(1):126-32. PubMed ID: 17258385
[TBL] [Abstract][Full Text] [Related]
17. SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate Cancer.
Schmidkonz C; Cordes M; Beck M; Goetz TI; Schmidt D; Prante O; Bäuerle T; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
Clin Nucl Med; 2018 Apr; 43(4):225-231. PubMed ID: 29401151
[TBL] [Abstract][Full Text] [Related]
18. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.
Vallabhajosula S; Nikolopoulou A; Babich JW; Osborne JR; Tagawa ST; Lipai I; Solnes L; Maresca KP; Armor T; Joyal JL; Crummet R; Stubbs JB; Goldsmith SJ
J Nucl Med; 2014 Nov; 55(11):1791-8. PubMed ID: 25342385
[TBL] [Abstract][Full Text] [Related]
19. Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer treated with extended pelvic lymph node dissection. A novel prediction tool.
Briganti A; Capitanio U; Abdollah F; Gallina A; Suardi N; Bianchi M; Tutolo M; Salonia A; Freschi M; Rigatti P; Montorsi F
Prostate; 2012 Apr; 72(5):499-506. PubMed ID: 22468270
[TBL] [Abstract][Full Text] [Related]
20. Identifying candidates for super-extended staging pelvic lymph node dissection among patients with high-risk prostate cancer.
Gandaglia G; Zaffuto E; Fossati N; Bandini M; Suardi N; Mazzone E; Dell'Oglio P; Stabile A; Freschi M; Montorsi F; Briganti A
BJU Int; 2018 Mar; 121(3):421-427. PubMed ID: 29063734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
